393 related articles for article (PubMed ID: 30230649)
1. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab.
Kimbara S; Fujiwara Y; Iwama S; Ohashi K; Kuchiba A; Arima H; Yamazaki N; Kitano S; Yamamoto N; Ohe Y
Cancer Sci; 2018 Nov; 109(11):3583-3590. PubMed ID: 30230649
[TBL] [Abstract][Full Text] [Related]
2. Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes.
Peiró I; Palmero R; Iglesias P; Díez JJ; Simó-Servat A; Marín JA; Jiménez L; Domingo-Domenech E; Mancho-Fora N; Nadal E; Villabona C
Endocrine; 2019 Jun; 64(3):605-613. PubMed ID: 30805887
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma.
Yano S; Ashida K; Nagata H; Ohe K; Wada N; Takeichi Y; Hanada Y; Ibayashi Y; Wang L; Sakamoto S; Sakamoto R; Uchi H; Shiratsuchi M; Furue M; Nomura M; Ogawa Y
BMC Endocr Disord; 2018 Jun; 18(1):36. PubMed ID: 29884162
[TBL] [Abstract][Full Text] [Related]
4. Risk of Thyroid Dysfunction in PD-1 Blockade Is Stratified by the Pattern of TgAb and TPOAb Positivity at Baseline.
Zhou X; Iwama S; Kobayashi T; Ando M; Arima H
J Clin Endocrinol Metab; 2023 Sep; 108(10):e1056-e1062. PubMed ID: 37084392
[TBL] [Abstract][Full Text] [Related]
5. Thyroid function and prevalence of anti-thyroperoxidase (TPO) and anti-thyroglobulin (Tg) antibodies in outpatients hospital setting in an area with sufficient iodine intake: influences of age and sex.
Legakis I; Manousaki M; Detsi S; Nikita D
Acta Med Iran; 2013; 51(1):25-34. PubMed ID: 23456581
[TBL] [Abstract][Full Text] [Related]
6. Thyroid function in Japanese adults as assessed by a general health checkup system in relation with thyroid-related antibodies and other clinical parameters.
Kasagi K; Takahashi N; Inoue G; Honda T; Kawachi Y; Izumi Y
Thyroid; 2009 Sep; 19(9):937-44. PubMed ID: 19678737
[TBL] [Abstract][Full Text] [Related]
7. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
8. Phenotypes of interferon-α-induced thyroid dysfunction among patients treated for hepatitis C are associated with pretreatment serum TSH and female sex.
Mammen JS; Ghazarian SR; Pulkstenis E; Subramanian GM; Rosen A; Ladenson PW
J Clin Endocrinol Metab; 2012 Sep; 97(9):3270-6. PubMed ID: 22689690
[TBL] [Abstract][Full Text] [Related]
9. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.
Wu L; Xu Y; Wang X; Cheng X; Zhang Y; Wang Y; Fan X; Zhao H; Liu H; Chai X; Zhang L; Wang M; Li N; Pan H; Lian X
Endocrine; 2023 Jul; 81(1):123-133. PubMed ID: 36867366
[TBL] [Abstract][Full Text] [Related]
10. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
Mazarico I; Capel I; Giménez-Palop O; Albert L; Berges I; Luchtenberg F; García Y; Fernández-Morales LA; De Pedro VJ; Caixàs A; Rigla M
J Endocrinol Invest; 2019 Dec; 42(12):1443-1450. PubMed ID: 31093955
[TBL] [Abstract][Full Text] [Related]
11. RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB.
O'Malley G; Lee HJ; Parekh S; Galsky MD; Smith CB; Friedlander P; Yanagisawa RT; Gallagher EJ
Endocr Pract; 2017 Oct; 23(10):1223-1231. PubMed ID: 29045188
[TBL] [Abstract][Full Text] [Related]
12. Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade.
Yamagami A; Iwama S; Kobayashi T; Zhou X; Yasuda Y; Okuji T; Ito M; Izuchi T; Ando M; Onoue T; Miyata T; Sugiyama M; Hagiwara D; Suga H; Banno R; Arima H
Endocr J; 2024 May; 71(5):515-526. PubMed ID: 38599854
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma.
Koizumi Y; Hirooka M; Hiraoka A; Ochi H; Tanaka T; Yukimoto A; Imai Y; Watanabe T; Yoshida O; Miyake T; Matsuura B; Michitaka K; Joko K; Abe M; Hiasa Y
Endocr J; 2019 Sep; 66(9):787-792. PubMed ID: 31142692
[TBL] [Abstract][Full Text] [Related]
14. Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.
Hwang Y; Kim W; Kwon SY; Yu HM; Kim JH; Choe WH
Korean J Intern Med; 2015 Nov; 30(6):792-800. PubMed ID: 26552454
[TBL] [Abstract][Full Text] [Related]
15. The prevalence of polycystic thyroid disease in hypothyroid patients with negative thyroid autoantibodies.
Kubota S; Maruta T; Fujiwara M; Hagiwara H; Tsujimoto N; Kudo T; Nishihara E; Ito M; Amino N; Miyauchi A
Thyroid; 2010 Nov; 20(11):1205-8. PubMed ID: 21062193
[TBL] [Abstract][Full Text] [Related]
16. Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade.
Kobayashi T; Iwama S; Yamagami A; Yasuda Y; Okuji T; Ito M; Zhou X; Ando M; Onoue T; Miyata T; Sugiyama M; Hagiwara D; Suga H; Banno R; Hase T; Morise M; Ito T; Kikumori T; Inoue M; Ando Y; Masuda N; Kawashima H; Hashimoto N; Arima H
J Clin Endocrinol Metab; 2022 Sep; 107(10):e4115-e4123. PubMed ID: 35918067
[TBL] [Abstract][Full Text] [Related]
17. Thyroid disorders and the prevalence of antithyroid antibodies in Shiraz population.
Karimi F; Kalantarhormozi MR; Dabbaghmanesh MH; Ranjbar Omrani G
Arch Iran Med; 2014 May; 17(5):347-51. PubMed ID: 24784864
[TBL] [Abstract][Full Text] [Related]
18. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
[TBL] [Abstract][Full Text] [Related]
19. [The association between baseline TPOAb and/or TgAb positivity and thyroid immune-related adverse events in patients with malignancies following treatment with immune checkpoint inhibitors].
Gao Y; Ye T; Wu LG; Xu Y; Wang X; Cheng XQ; Zhang YL; Wang YY; Fan XR; Zhao HT; Liu H; Chai XF; Zhang L; Wang MZ; Li NS; Lian XL
Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(12):963-969. PubMed ID: 38514346
[No Abstract] [Full Text] [Related]
20. Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?
Pani F; Atzori F; Baghino G; Boi F; Tanca L; Ionta MT; Mariotti S
Thyroid; 2015 Nov; 25(11):1255-61. PubMed ID: 26414109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
